Antibodies, Bispecific – Page 2

‘Deviated from the core’: Akeso CEO tries to reset expectations of bispecific’s survival readout amid market tumult

6 months ago talkbio0Tagged Antibodies, Bispecific, Ivonescimab, Keytruda, Keytruda head-to-head trial, Market, Non-Small Cell Lung Carcinoma, Overall Survival, PD-1xVEGF, Reaction, summit

Ivonescimab, PD-1xVEGF bispecific antibody, Overall survival (OS) readout, Keytruda head-to-head trial, HARMONi-2 trial, Non-small cell lung cancer (NSCLC), Market reaction, Summit Therapeutics

Stealth biotech bags rights to VelaVigo bispecific in $440M deal

6 months ago talkbio0Tagged Antibodies, Bispecific, China, stealth, VelaVigo

VelaVigo, Antibodies, Bispecific, stealth, China

Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology

6 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune, Collaboration, development aspects, Earendil Labs, Immunology, Inflammatory Bowel Diseases, sanofi

Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects

Sanofi Expands Immunology Pipeline with $600M Acquisition of Dren Bio’s Novel B-Cell Depleting Bispecific Antibody

7 months ago talkbio0Tagged Antibodies, Bispecific, Autoimmune Diseases, B-cell depletion, CD20-directed therapy, Immunology pipeline, Myeloid cell engager, Phagocytosis

Bispecific antibody, Myeloid cell engager, B-cell depletion, Autoimmune diseases, Immunology pipeline, Phagocytosis, CD20-directed therapy

ImmunoPrecise Antibodies Secures $8-10M Partnership for Novel Cancer Therapeutics Development

7 months ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug, Antibody-Drug Conjugates, B-cell Select ™ technology, Cancer Therapeutic Procedure, Discover, ImmunoPrecise Antibodies, Immunostimulating conjugate (antigen)

ImmunoPrecise Antibodies, Antibody-Drug Conjugates (ADCs), bispecific antibodies, cancer treatment, AI-driven discovery, B-cell Select™ technology

Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations

8 months ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug, Antibody-Drug Conjugates, Clinical Trials, Ivonescimab, PD-1/VEGF, Pfizer, Solid Neoplasm, summit

Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials

Bambusa Therapeutics Secures $90M Series A Funding to Advance Bispecific Antibodies for I&I Disorders

8 months ago talkbio0Tagged Antibodies, Bispecific, Bambusa Therapeutics, Capital Management, Funding, Immunology, Inflammation, Rheumatoid Arthritis, Series

Bambusa Therapeutics, bispecific antibodies, immunology, inflammation, Series A funding, RA Capital Management, I&I disorders

InnoCare and KeyMed Secure $520M Licensing Deal for Bispecific Antibody with RTW-Built Biotech

9 months ago talkbio0Tagged Antibodies, Bispecific, InnoCare, Investments, KeyMed, Licensing, RTW

InnoCare, KeyMed, Bispecific Antibody, RTW Investments, Licensing Deal, $520M

I-Mab Reprioritizes Pipeline, Halts CD73 Antibody Development to Focus on Givastomig

9 months ago talkbio0Tagged 5'-NUCLEOTIDASE, Antibodies, Antibodies, Bispecific, Givastomig, I-Mab, Immunotherapy for cancer, metastatic gastric cancers, pipeline, reshuffle, Uliledlimab

I-Mab, pipeline reshuffle, CD73 antibody, uliledlimab, givastomig, CLDN18.2 x 4-1BB bispecific antibody, cancer immunotherapy, metastatic gastric cancers

Angitia Biopharmaceuticals Secures $120 Million in Series C Funding to Develop Novel Musculoskeletal Treatments

10 months ago talkbio0Tagged Angitia Biopharmaceuticals, Antibodies, Bispecific, Clinical Development, Musculoskeletal Diseases, Osteogenesis Imperfecta, Osteoporosis, Series, Spinal fusion (procedure)

Angitia Biopharmaceuticals, Series C funding, Musculoskeletal diseases, Osteoporosis, Osteogenesis imperfecta (OI), Spinal fusion, Bispecific antibodies, Clinical development